2-chloro-6-methyl-4-(2-methoxyphenyl)pyrimidine | 219840-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-6-methyl-4-(2-methoxyphenyl)pyrimidine
• 英文别名: 2-chloro-4-(2-methoxy-phenyl)-6-methyl-pyrimidine；2-chloro-4-(2-methoxyphenyl)-6-methylpyrimidine
• CAS: 219840-89-8
• 化学式: C₁₂H₁₁ClN₂O
• 分子量: 234.685
• InChiKey: SFQJAVGZCUXBDV-UHFFFAOYSA-N

物化性质

• 沸点：
  350.7±27.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-6-methyl-4-(2-methoxyphenyl)pyrimidine 在 sodium hydride 作用下， 以 二甲基亚砜 、 甲苯 为溶剂， 生成 N-(2-Bromo-4,6-dimethoxyphenyl)-N-ethyl-4-(2-methoxyphenyl)-6-methyl-2-pyrimidineamine
  参考文献：
  名称：

  4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists

  摘要：

  A series of 4-aryl-2-(N-ethylanilino)pyrimidines has been synthesized as corticotropin-releasing hormone (CRH) inhibitors. The effect of substitution on each aromatic ring on receptor binding was investigated. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00132-8
• 作为产物：
  描述：

  2,4-二氯-6-甲基嘧啶 、 2-甲氧基苯基硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.25h， 生成 2-chloro-6-methyl-4-(2-methoxyphenyl)pyrimidine
  参考文献：
  名称：

  Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing Protein Inhibitors

  摘要：

  Valosine-containing protein (VCP), also known as p97 or cdc48 in yeast, is a highly abundant protein belonging to the AAA ATPase family involved in a number of essential cellular functions, including ubiquitin-proteasome mediated protein degradation, Golgi reassembly, transcription activation, and cell cycle control. Altered expression of VCP has been detected in many cancer types sometimes associated with poor prognosis. Furthermore, VCP mutations are causative of some neurodegenerative disorders. In this paper we report the discovery, synthesis, and structure-activity relationships of substituted 2-aminopyrimidines, representing a new class of reversible VCP inhibitors. This class of compounds, identified in a HTS campaign against recombinant VCP, has been progressively expanded and manipulated to increase biochemical potency and gain cellular activity.

  DOI：

  10.1021/jm501313x

文献信息

• Aryl- and arylamino- substituted heterocycles as corticotropin releasing
  申请人：DuPont Pharmaceuticals Company

  公开号：US06103737A1

  公开（公告）日：2000-08-15

  Corticotropin releasing factor (CRF) antagonists of formula I: ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  促肾上腺皮质激素释放因子（CRF）拮抗剂的化学式I：##STR1##及其在治疗精神障碍和神经疾病、焦虑相关障碍、创伤后应激障碍、上核性麻痹和进食障碍以及治疗与精神病理障碍和压力相关的结肠过敏性疾病以及哺乳动物免疫、心血管或心脏相关疾病的用途。
• INHIBITORS OF PROTEIN KINASES
  申请人：Schauerte Heike

  公开号：US20100168144A1

  公开（公告）日：2010-07-01

  The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

  本发明涉及抑制细胞周期依赖性激酶及其治疗应用。此外，该发明涉及预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增生性疾病、传染性疾病、心血管疾病和神经退行性疾病的方法，包括给予至少一种细胞周期依赖性激酶抑制剂的有效量。公式（I）。
• Inhibitors of Protein Kinases
  申请人：AstraZeneca AB

  公开号：US20150011576A1

  公开（公告）日：2015-01-08

  The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

  本发明涉及细胞周期依赖性激酶抑制剂及其治疗应用。此外，本发明涉及通过给予至少一种细胞周期依赖性激酶抑制剂的有效剂量来预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、感染性疾病、心血管疾病和神经退行性疾病的方法。
• Inhibitors of protein kinases
  申请人：Schauerte Heike

  公开号：US08507511B2

  公开（公告）日：2013-08-13

  The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

  本发明涉及抑制细胞周期依赖性激酶及其治疗应用的药物。此外，本发明涉及通过给予至少一种细胞周期依赖性激酶抑制剂有效剂量来预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增生性疾病、感染性疾病、心血管疾病和神经退行性疾病的方法。公式（I）：
• WO2008/129071
  申请人：——

  公开号：——

  公开（公告）日：——